Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 5:26 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 553–576 of 582 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: methylprednisolone acetate Clear all
Active, not recruiting Phase 3 Interventional

A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma

NCT06097364
View directory record Official record
Conditions
Follicular Lymphoma (FL)
Interventions
Odronextamab, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone/Prenisolone
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
733 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
9
States / cities
Plantation, Florida • Noblesville, Indiana • Wichita, Kansas + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Oct 15, 2026, 5:26 PM EDT
Recruiting Phase 3 Interventional

A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)

NCT06925737
View directory record Official record
Conditions
Prostate Cancer, Prostatic Neoplasms
Interventions
Ifinatamab deruxtecan, Docetaxel, Prednisone, Rescue Medication
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,440 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
55
States / cities
Phoenix, Arizona • Clovis, California • Duarte, California + 43 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 15, 2026, 5:26 PM EDT
Completed Phase 1 Interventional

Laboratory-Treated Lymphocyte Infusion After Haploidentical Donor Stem Cell Transplant

NCT00376480
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndromes
Interventions
anti-thymocyte globulin, peripheral blood lymphocyte therapy, fludarabine phosphate, methylprednisolone, thiotepa, allogeneic hematopoietic stem cell transplantation, in vitro-treated peripheral blood stem cell transplantation, total-body irradiation
Biological · Drug · Procedure + 1 more
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
Up to 50 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2018
U.S. locations
6
States / cities
Los Angeles, California • Gainesville, Florida • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2019 · Synced Oct 15, 2026, 5:26 PM EDT
Completed Phase 3 Interventional Results available

Study of T-PRED(TM) Compared to Pred Forte(R) II

NCT00854061
View directory record Official record
Conditions
Cataract
Interventions
T-Pred, Pred Forte
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Oct 20, 2020 · Synced Oct 15, 2026, 5:26 PM EDT
Recruiting No phase listed Observational

Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma

NCT00576069
View directory record Official record
Conditions
Asthma
Interventions
budesonide/formoterol, fluticasone/salmeterol, mometasone/formoterol, Prednisone
Drug
Lead sponsor
Gelb, Arthur F., M.D.
Individual
Eligibility
10 Years to 95 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2027
U.S. locations
1
States / cities
Lakewood, California
Source: ClinicalTrials.gov public record
Updated Oct 26, 2023 · Synced Oct 15, 2026, 5:26 PM EDT
Completed Phase 3 Interventional Results available

Tacrolimus/Everolimus Versus Tacrolimus/Enteric-Coated Mycophenolate Sodium

NCT01680861
View directory record Official record
Conditions
Transplant; Failure, Kidney
Interventions
Tacrolimus, Everolimus, Enteric Coated Mycophenolate Sodium (EC-MPS), Corticosteroids
Drug
Lead sponsor
Gaetano Ciancio
Other
Eligibility
18 Years to 75 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 15, 2016 · Synced Oct 15, 2026, 5:26 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution in Non-Infectious Anterior Uveitis

NCT02517619
View directory record Official record
Conditions
Anterior Uveitis
Interventions
Dexamethasone Phosphate Ophthalmic Solution, Prednisolone Acetate Ophthalmic (1%)
Drug
Lead sponsor
Eyegate Pharmaceuticals, Inc.
Industry
Eligibility
12 Years to 85 Years
Enrollment
251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 26, 2018 · Synced Oct 15, 2026, 5:26 PM EDT
Terminated Phase 3 Interventional

Comparison of Three Treatments for Pneumocystis Pneumonia in AIDS Patients

NCT00000730
View directory record Official record
Conditions
Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions
Trimetrexate glucuronate, Methylprednisolone, Pentamidine isethionate, Sulfamethoxazole-Trimethoprim, Leucovorin calcium
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1989
U.S. locations
1
States / cities
West Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Oct 15, 2026, 5:26 PM EDT
Enrolling by invitation Phase 4 Interventional

Post-operative Methylprednisolone Taper Course for Orthopedic Surgery

NCT03661645
View directory record Official record
Conditions
Orthopedic Surgeries
Interventions
10 mg IV dexamethasone & 6 day oral methylprednisolone taper, 10 mg IV dexamethasone
Drug · Other
Lead sponsor
Emory University
Other
Eligibility
18 Years to 95 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2029
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Oct 15, 2026, 5:26 PM EDT
Completed Early Phase 1 Interventional

Medrol Dose Packs for Post-Operative Pain Control

NCT06453083
View directory record Official record
Conditions
Pain
Interventions
Placebo, Medrol
Drug
Lead sponsor
University of Utah
Other
Eligibility
10 Years to 21 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jan 7, 2025 · Synced Oct 15, 2026, 5:26 PM EDT
Completed Phase 1 Interventional

Pulse ACTH vs. MP for MS

NCT01049451
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
ACTH, Methylprednisolone
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 19, 2017 · Synced Oct 15, 2026, 5:26 PM EDT
Not listed Phase 1Phase 2 Interventional

Evaluating Safety and Efficacy of TOL101 Induction Versus Anti-Thymocyte Globulin to Prevent Kidney Transplant Rejection

NCT01154387
View directory record Official record
Conditions
End Stage Renal Disease, Renal Transplant
Interventions
Anti-Thymocyte Globulin, TOL101, Steroids, Tacrolimus, Mycophenolate mofetil (MMF)
Drug
Lead sponsor
Tolera Therapeutics, Inc
Industry
Eligibility
18 Years to 60 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
12
States / cities
Aurora, Colorado • Lexington, Kentucky • Ann Arbor, Michigan + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2013 · Synced Oct 15, 2026, 5:26 PM EDT
Terminated Not applicable Interventional Results available

Comparing Acular LS and Pred Forte in Reducing Post-selective Laser Trabeculoplasty Anterior Chamber Flare and Cells

NCT00478036
View directory record Official record
Conditions
Open Angle Glaucoma
Interventions
Acular LS, Pred Forte, Refresh Tears
Drug · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 7, 2016 · Synced Oct 15, 2026, 5:26 PM EDT
Completed Phase 2 Interventional Results available

Rituximab, Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Stage II, III, or IV Follicular NHL

NCT00732498
View directory record Official record
Conditions
Lymphoma
Interventions
Methylprednisolone, Etoposide, Cytarabine, Cisplatin, Rituximab, In-Zevalin, Y-Zevalin
Drug
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2018
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 4, 2019 · Synced Oct 15, 2026, 5:26 PM EDT
Completed Phase 2 Interventional Results available

Allogeneic Transplantation From Related Haploidentical Donors

NCT00185692
View directory record Official record
Conditions
Blood Cancer, Leukemia, Graft Versus Host Disease, Malignancy, CLL, NHL, Hodgkin's Disease, MDS
Interventions
non-myeloablative hematopoietic cell transplantation, Anti-Thymocyte Globulin, Cyclosporine, Mycophenolate Mofetil, G-CSF, Solumedrol, Acetaminophen, Diphenydramine, Hydrocortisone
Procedure · Drug
Lead sponsor
Stanford University
Other
Eligibility
12 Months and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2010
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 4, 2019 · Synced Oct 15, 2026, 5:26 PM EDT
Completed No phase listed Observational

Dexamethasone and COVID-19 Inpatient Mortality

NCT04926571
View directory record Official record
Conditions
Coronavirus
Interventions
Dexamethasone Oral
Drug
Lead sponsor
Aetion, Inc.
Other
Eligibility
Not listed
Enrollment
14,105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 18, 2023 · Synced Oct 15, 2026, 5:26 PM EDT
Completed Phase 2 Interventional

Phase II Randomized Study of Muromonab-CD3, Cyclosporine, Methylprednisolone, and Prednisone in Patients With Giant Cell Myocarditis

NCT00004482
View directory record Official record
Conditions
Myocarditis, Giant Cell Myocarditis
Interventions
Cyclosporine, methylprednisolone, Muromonab-CD3, prednisone
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2006
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 9, 2010 · Synced Oct 15, 2026, 5:26 PM EDT
Recruiting Phase 1Phase 2 Interventional

Study of Complication Rates in Cataract Surgery Patients Treated With Combined Pre-operative NSAID, OMIDRIA, and Subconjunctival Triamcinolone Acetonide Compared With Peri-operative SOC

NCT06681688
View directory record Official record
Conditions
Cataract
Interventions
Omidria, {0.3%-1% Intraocular Solution}, VIGAMOX {0.5% moxifloxacin hydrochloride}, Kenalog {0.4 ml, 10mg/ml, triamcinolone acetonide}, Ketorolac (0.5%) {Toradol}, moxifloxacin (0.5%) {VIGAMOX}, prednisolone acetate (1%) {Pred Forte}
Drug
Lead sponsor
Inder Paul Singh, M.D.
Other
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
2
States / cities
Venice, Florida • Racine, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 29, 2024 · Synced Oct 15, 2026, 5:26 PM EDT
Completed Phase 2 Interventional Results available

Reduced Intensity Conditioning for Hemophagocytic Syndromes or Selected Primary Immune Deficiencies (BMT CTN 1204)

NCT01998633
View directory record Official record
Conditions
Hemophagocytic Lymphohistiocytosis, Chronic Active Epstein-Barr Virus Infection, Chronic Granulomatous Disease, HIGM-1, Leukocyte Adhesion Deficiency, IPEX
Interventions
Hematopoietic Stem Cell Transplant
Biological
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
4 Months to 45 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
19
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Atlanta, Georgia + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2022 · Synced Oct 15, 2026, 5:26 PM EDT
Completed Phase 2 Interventional

Phase II Study of Bone Marrow Transplantation Using Related Donors in Patients With Aplastic Anemia

NCT00004323
View directory record Official record
Conditions
Aplastic Anemia
Interventions
anti-thymocyte globulin, cyclophosphamide, cyclosporine, mesna, methotrexate, methylprednisolone
Drug
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
0 Years to 55 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1995
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 15, 2026, 5:26 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 PK Interaction Study Between VX-509 and Prednisone or Methylprednisolone in Healthy Male Subjects

NCT01886209
View directory record Official record
Conditions
Drug Interactions
Interventions
Prednisone, VX-509, Methylprednisolone
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 14, 2013 · Synced Oct 15, 2026, 5:26 PM EDT
Completed Phase 1Phase 2 Interventional

Phase I/II Study of Total Body Irradiation, Cyclophosphamide, and Fludarabine Followed by Alternate Donor Hematopoietic Cell Transplantation in Patients With Fanconi's Anemia

NCT00005898
View directory record Official record
Conditions
Fanconi's Anemia
Interventions
anti-thymocyte globulin, cyclophosphamide, cyclosporine, filgrastim, fludarabine, methylprednisolone
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
0 Years to 34 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 15, 2026, 5:26 PM EDT
Completed Phase 3 Interventional

A Study Assessing the Safety and Efficacy of Dextenza® for the Treatment of Ocular Pain and Inflammation Following Surgery for Pediatric Cataract

NCT04539548
View directory record Official record
Conditions
Cataract
Interventions
Dextenza Ophthalmic Insert, Prednisolone acetate ophthalmic suspension USP 1%
Drug
Lead sponsor
Ocular Therapeutix, Inc.
Industry
Eligibility
0 Years to 5 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
14
States / cities
Aurora, Colorado • Fort Collins, Colorado • Jacksonville, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2024 · Synced Oct 15, 2026, 5:26 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Stem Cell Transplantation for Stiff Person Syndrome (SPS)

NCT02282514
View directory record Official record
Conditions
Stiff-Person Syndrome
Interventions
Autologous Hematopoietic Stem Cells, Cyclophosphamide, Mesna, rATG, Methylprednisolone, G-CSF, Rituxan
Biological · Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 60 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 27, 2021 · Synced Oct 15, 2026, 5:26 PM EDT